About X-Chem
X-Chem is a Healthcare company based in Waltham (United States) founded in 2009, and was acquired by Enko Chem in June 2022. Small molecule drug discovery platform is provided to researchers. X-Chem has raised $8.5 million across 1 funding round from investors including PPD, Enko Chem and GHO Capital. The company has 51 employees. X-Chem has completed 4 acquisitions, including Avisyn, ComInnex and Glamorous AI. X-Chem offers products and services including DEL Screening, ReadiDEL, ReadiBLOX, and ArtemisAI. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is X-CHEM INC. Its competitors include STRmix and The Total Body Approach.
Company details
X-Chem was founded in 2009 and is based in Waltham, United States. Operations center on a biotechnology platform for small molecule drug discovery, known as DNA-Encoded X-Chem (DEX). Libraries of small molecules tethered to DNA tags, which track synthetic history, are generated through combinatorial synthesis. These mixtures are screened via affinity binding to targets, with bound compounds detected by DNA sequencing for therapeutic development.
- Headquarters Waltham, United States
- Employees 51
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website x-chemrx.com
- Social LinkedIn X
- Acquired by Enko Chem (Jun 2022)
- Legal Name X-Chem Inc
Products & Services of X-Chem
X-Chem offers a comprehensive portfolio of products and services, including DEL Screening, ReadiDEL, ReadiBLOX, and ArtemisAI.
Service for screening DNA-encoded libraries to identify drug candidates.
Pre-built DNA-encoded library for rapid drug discovery research.
Modular building blocks for custom medicinal chemistry applications.
AI tool for analyzing molecular interactions in drug development.
Funding Insights of X-Chem
X-Chem has successfully raised a total of $8.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.5 million completed in December 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.5M
- Total Rounds 1
- Last Round Series A — $8.5M
- First Round $8.5M
(Dec 2012)
All 1 funding rounds of X-Chem with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2012 | $8.5M | Series A | – | – | – |
3 investors in total: 3 institutional.
Investors in X-Chem
X-Chem has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include PPD, Enko Chem and GHO Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specialist healthcare investment advisory services are provided by GHO Capital. | ghocapital.com | London, United Kingdom | ||
CRO providing diversified clinical development services | 1985 | ppd.com | Wilmington, United States | |
Develops and supplies agriculture crop inputs | 2017 | enkochem.com | Boston, United States |
Investor details for X-Chem
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of X-Chem
69 people are tracked at X-Chem (12 in leadership, 57 in team); the tracked headcount is 51.
| Name | Role | Group |
|---|---|---|
Jordan Palfrey | Director Of Business Development | Leadership |
Sydney Peacock | Director Of Information Technology | Leadership |
Matthew A. Clark | President And Chief Scientific Officer | Leadership |
Sana Bazzaz | Associate Director, Alliance & Project Managment | Leadership |
Tatiana Demidova-Rice | Senior Director, BD | Leadership |
Shawn Johnstone PhD | Executive Director Of Chemistry | Leadership |
Erin Davis | Chief Technology Officer | Leadership |
Paolo Centrella | Senior Director, Library Chemistry | Leadership |
Anna Amcheslavsky, PhD. | Sr. Director of Business Development | Leadership |
Ying Zhang | Vice President, Chemistry | Leadership |
Miklós István Szávuly | Head Of Laboratory | Leadership |
Marie-Aude Guié | Vice President, Scientific Computing & Data Science | Leadership |
Sean Kepper | IT Consultant | Team |
Fabien Lindeperg | Research Scientist | Team |
Anne Liao | Analytical Scientist | Team |
Ngocdung Ngo | Principal Research Associate | Team |
Raju Ch. N | Senior Scientist | Team |
Ryan Walsh | Principal Research Scientist, Cheminformatics | Team |
Shawn Parisien Collette | Research Scientist | Team |
Temilolu Idowu, PhD | Scientist | Team |
49 more people are available in the full profile.
Complete people profiles for X-Chem
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by X-Chem
X-Chem has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Avisyn, ComInnex and Glamorous AI.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Preclinical studies for biopharma drug discovery are conducted. | glamorous.ai | London, United Kingdom | 2020 | Oct 2021 | •••• | |
Custom chemical synthesis and business development services are provided. | cominnex.com | Budapest, Hungary | 2006 | Oct 2021 | •••• | |
Scientific sourcing services are offered by Avisyn as a CRO. | avisyn.com | San Diego, United States | 2016 | Jan 2021 | •••• | |
CRO offers synthetic, computational, analytical and in vitro and in vivo drug discovery services | intellisynrd.com | Montreal, Canada | 2011 | Jan 2021 | •••• |
Complete acquisition details for X-Chem
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of X-Chem
9 dated milestones of X-Chem across 13 years, from founding to its latest funding, stage changes and deals.
- Founded X-Chem is founded.
- Funding First funding round of $8.5M.
- Exit Acquired by PPD.
- Exit Acquired by GHO Capital Partners.
- Acquisition Acquires Avisyn.
- Acquisition Acquires IntelliSyn.
- Acquisition Acquires ComInnex.
- Acquisition Acquires Glamorous AI.
- Exit Acquired by Enko Chem.
Competitors of X-Chem
X-Chem has 2 listed competitors in our database. They include STRmix and The Total Body Approach.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| strmix.com | 2013 | Akron, United States | Develops software for forensic DNA profile analysis, interpretation, and evidence processing. | |||
| thetotalbodyapproach.com | 2014 | Waterbury, United States | Music producer creating remixes, new releases, and podcasts for fan engagement. |
Detailed competitors of X-Chem
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of X-Chem
The website of X-Chem (x-chemrx.com) receives about 3.7K visits a month and ranks #5,330,424 among all websites worldwide, #6,019 in Biotechnology and Pharmaceuticals.
- Monthly visits3.7K
▲ 16.3% vs previous month
- Unique visitors1.3K
per month
- Global rank#5,330,424
among all websites
- Category rank#6,019
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.7
- Average visit16 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with X-Chem. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medidata.com | 100% | 87K | #373,122 | View details | |
bioworld.com | bioworld.com | 90% | #311,180 | – | |
| pharmaceutical-technology.com | 54% | #316,052 | View details | ||
| google.com | 39% | 85.8B | #1 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as X-Chem (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about X-Chem
Complete news archive for X-Chem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about X-Chem
X-Chem was founded in 2009 and raised its 1st funding round 3 years after it was founded.
X-Chem is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
X-Chem is a funded company, having raised a total of $8.5M across 1 funding round to date. The company's 1st funding round was a Series A of $8.5M, raised on Dec 2012.
X-Chem has 51 employees.
X-Chem was founded in 2009 and is based in Waltham, United States. Operations center on a biotechnology platform for small molecule drug discovery, known as DNA-Encoded X-Chem (DEX). Libraries of small molecules tethered to DNA tags, which track synthetic history, are generated through combinatorial synthesis. These mixtures are screened via affinity binding to targets, with bound compounds detected by DNA sequencing for therapeutic development.
X-Chem's top competitors include STRmix and The Total Body Approach.
X-Chem offers DEL Screening, ReadiDEL, ReadiBLOX, and ArtemisAI.
X-Chem has made 4 acquisitions, including Avisyn, ComInnex, and Glamorous AI.
X-Chem has 3 investors. Key investors include PPD, Enko Chem, and GHO Capital.
X-Chem operates through X-Chem Inc.
Yes. X-Chem was acquired by Enko Chem in June 2022.